News archive
Showing 687 results
March 2008
-
Media ReleaseVIDEO: Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy- Post-unblinding analysis of MA-17 trial data provides evidence for potential benefit of starting Femara up to seven years after finishing tamoxifen- Femara only member of aromatase inhibitor class…
-
Media ReleaseVIDEO: Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
February 2008
-
Media ReleaseEverolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy- Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus- Everolimus (RAD001) tablet, taken once daily,…
-
Media ReleaseEverolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
January 2008
-
Media ReleaseVideo and Photo: Tekturna HCT®, a Single-tablet Combination of Tekturna®* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure- Tekturna HCT combines first approved direct renin inhibitor with the diuretic hydrochlorothiazide (HCTZ) in a single tablet- Data show combination of Tekturna and HCTZ resulted in significant…
-
Media ReleaseVideo and Photo: Tekturna HCT®, a Single-tablet Combination of Tekturna®* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
December 2007
-
Media ReleasePhoto: New Data Show Gleevec® Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment- Risk of disease progression continues to drop from the second year of treatment; no patients taking Gleevec in sixth year progressed from initial disease phase- Long-term survival trend may suggest…
-
Media ReleasePhoto: New Data Show Gleevec® Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment